相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Cassandra J. Vandenberg et al.
BLOOD (2013)
ABT-199: Taking Dead Aim at BCL-2
Matthew S. Davids et al.
CANCER CELL (2013)
Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo
R. Soderquist et al.
LEUKEMIA (2013)
Apoptosis therapy: driving cancers down the road to ruin
Douglas R. Green et al.
NATURE MEDICINE (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
Delphine Merino et al.
BLOOD (2012)
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Stefan P. Glaser et al.
GENES & DEVELOPMENT (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
R. W. Rooswinkel et al.
CELL DEATH & DISEASE (2012)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies
Seong Lin Khaw et al.
PATHOLOGY (2011)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
K. D. Mason et al.
LEUKEMIA (2009)
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
Delfine Y. H. Hallaert et al.
BLOOD (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates γ irradiation-induced thymic lymphoma development
Verena Labi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
Richard Lock et al.
PEDIATRIC BLOOD & CANCER (2008)
Bax and the mitochondrial permeability transition cooperate in the release of cytochrome c during endoplasmic reticulum-stress-induced apoptosis
D. Zhang et al.
CELL DEATH AND DIFFERENTIATION (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction
Miriam Erlacher et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells
Nuno L. Alves et al.
IMMUNITY (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
Rapid generation of inducible mouse mutants -: art. no. e12
J Seibler et al.
NUCLEIC ACIDS RESEARCH (2003)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
Tissue expression and subcellular localization of the pro-survival molecule Bcl-w
LA O'Reilly et al.
CELL DEATH AND DIFFERENTIATION (2001)
The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues
T Lindsten et al.
MOLECULAR CELL (2000)
分享论文
